Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

ABSTRACT:

Introduction

Sepsis remains a leading cause of death worldwide. Despite years of extensive research, effective drugs that inhibit the pro-inflammatory effects of lipopolysaccharide (LPS) and improve outcome when added to conventional sepsis treatments are lacking. Eritoran tetrasodium (E5564) is a promising candidate therapy for sepsis belonging to a new class of such drugs which inhibit LPS-induced inflammation by blocking toll-like receptor 4.

Areas covered

This review focuses on the rationale for the use of eritoran tetrasodium in sepsis as well as on its pharmacokinetics, pharmacodynamics, efficacy and safety. Preclinical and clinical studies from a MEDLINE/PubMed literature search in August 2010 with the search terms 'eritoran' and 'E5564' are discussed.

Expert opini

SUBMITTER: Barochia A 

PROVIDER: S-EPMC3065179 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature